About AQEMIA

Aqemia uses generative AI and quantum physics to discover new medicines for major diseases including oncology. The proprietary platform, QEMI, combines fast physics algorithms with machine learning to design novel drug molecules without relying on past experimental data, enabling faster exploration of chemical space and prediction of molecular interactions with disease targets. Born from 12 years of academic research in theoretical physics at Oxford, Cambridge and ENS/CNRS Paris, Aqemia builds a scalable drug discovery engine capable of advancing dozens of drug candidates. The company pursues innovative therapies for unsolved diseases through a physics-first approach that delivers higher probability of success.